InvestorsHub Logo
Followers 9
Posts 740
Boards Moderated 0
Alias Born 01/15/2014

Re: None

Monday, 06/06/2016 11:29:29 PM

Monday, June 06, 2016 11:29:29 PM

Post# of 18432
Google this- Fresenius-Exthera medical

ExThera Seeks to Commercialize Technology to Remove Pathogens From Blood

ExThera Medical Corp., a developer of blood filtering technology, has obtained financing to support European and U.S. clinical trials, regulatory approvals, and manufacturing of the its proprietary therapeutic SeraphMicrobindAffinity Blood Filter aimed at reducing mortality and complications from bloodstream infections and blood-borne diseases.

A Series B financing round was closed with an equity investment led by new investor Fresenius Medical Care Ventures GmbH. The round included existing investors, and the conversion of the company’s convertible note, for a total of $15.3 million. Other terms were not disclosed.

http://www.mdtmag.com/news/2016/06/exthera-seeks-commercialize-technology-remove-pathogens-blood

Now, what was that reason AEMD chose not to go after EU approval first?

Fresenius est. 2016 revenues= 18 billion
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AEMD News